Aethlon Medical Inc.

Aethlon Medical Inc. creates affinity biofiltration devices to treat life-threatening diseases. The company's lead therapeutic candidate is the Aethlon Hemopurifier, a first-in-class device that targets the rapid elimination of infectious viruses and cancer-promoting exosomes from the circulatory system of treated individuals.

Expert Comments:

Kayt Sukel, Fortune (9/10/15)
"Current trends also have companies looking at the use of sensors, robotics and analytics to better understand the nature of infectious disease; one example. . .is Aethlon Medical Inc.'s Hemopurifier, a bio-filtration device that captures viruses and toxic proteins in the blood. . .Hemopurifier can be used for the treatment of Ebola, as well as for HIV, hepatitis C and other illnesses. TIME Magazine named the device one of the best inventions of 2014." Read the full story here.

"Aethlon Medical Inc. uplisted to the NASDAQ in mid-July. . .the company uses dialysis-like affinity and filtration platforms to remove cancer-causing agents from the circulatory system. Aethlon has approved products that remove viruses, and is now also targeting breast cancer." read more >

"Aethlon Medical Inc. has a product called Hemopurifier, an extracorporeal blood filter used with typical blood circulatory equipment, such as dialysis machines. Initially the company developed the device to remove the hepatitis C virus (HCV) from the blood, and it has shown some success in that regard. In fact, a small, U.S.-based clinical study with HCV patients recently started. But it may have more utility than in just HCV. In fact, Hemopurifier was used with an Ebola patient who became infected during the recent outbreak in West Africa. . .prior to Hemopurifier administration, the patient had multiple organ failure, was unconscious and had a viral load of 400,000 (400K) virus copies/ml. Following a 6.5-hour treatment with Hemopurifier viral load was 1K virus copies/ml. Hemopurifier captured 253 million copies of Ebola. . .the fact that it captured a significant amount of the virus certainly seems encouraging. Aethlon is now seeking Humanitarian Device Exemption from the FDA, which would allow use of Hemopurifier for Ebola in emergency situations. The company is also considering initiation of Ebola studies in both the U.S. and Canada. . ." read more >

Amit Tandon, SeeThruEquity (7/8/15)
"Aethlon Medical Inc. announced that its shares would be uplisting to the NASDAQ Capital Market. Clearly the move to NASDAQ represents a significant accomplishment for the company, which has been striving for this goal for some time. We expect the transition to have a positive effect on Aethlon's liquidity, improve the company's visibility and also open it up to new potential mutual funds, pensions and other institutional investors who may have been restricted from investing in the company while it traded on the OTC Marketplace."

Amit Tandon, SeeThruEquity (2/13/15)
"Aethlon Medical Inc. has increased its net worth by approximately $16M since the end of FY/14, with no notes in default and positive shareholders' equity and working capital as of December 31, 2014. . .the company announced the launch of an FDA approved clinical study testing the Aethlon Hemopurifier. . .this announcement comes on the heels of the earlier announcement that the FDA had approved the testing in Ebola patients of Aethlon's Hemopurifier device."

Brian Marckx, Zacks Equity Research (2/11/15)
"Aethlon Medical Inc.'s novel blood filtration device could have utility in the treatment of Hepatitis-C, HIV, sepsis, cancer, pandemic diseases and bioterror applications. . .management has been very resilient and successful in pursuing high-potential opportunities in other areas including Ebola, cancer, Alzheimer's disease and CTE. . .while we had concerns about risks such as a previously shaky balance sheet and reliance on a single target market, the company's substantive progress in allaying these concerns prompted our recent upgrade in recommendation from Neutral to Outperform."

Experts Following This Company

Caroline Corner, Managing Director, Equity Research – Cantor Fitzgerald
Brian Marckx, CFA – Zacks Small-Cap Research
Amit Tandon, Director of Research – SeeThruEquity

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Aethlon Medical Inc. Content